We are live on ! Find out more
INDP icon

Indaptus Therapeutics
INDP

15 hedge funds and large institutions have $1.06M invested in Indaptus Therapeutics in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

15% more funds holding

Funds holding: 13 → 15 (+2)

0.01% more ownership

Funds ownership: 0.24% → 0.26% (+0.01%)

32% less capital invested

Capital invested by funds: $1.57M → $1.06M (-$509K)

Holders
15
Holders Change
+2
Holders Change %
+15.38%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
5
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$37.1K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$12.4K
3
Renaissance Technologies
Renaissance Technologies
New York
+$11.3K
4
UBS Group
UBS Group
Switzerland
+$7.99K
5
TRCT
Tower Research Capital (TRC)
New York
+$3.77K

Top Sellers

Rank Fund Capital Flow
1
IHL
Investment House LLC
California
-$943
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$451K +$12.4K +197 +2%
IHL
2
Investment House LLC
California
$180K -$943 -15 -0.4%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$97K – – –
SAM
4
Strategy Asset Managers
California
$79.8K – – –
PVI
5
Pine Valley Investments
New Jersey
$77.9K – – –
Renaissance Technologies
6
Renaissance Technologies
New York
$52K +$11.3K +179 +21%
VCM
7
Vivaldi Capital Management
Illinois
$40K – – –
State Street
8
State Street
Massachusetts
$34.5K – – –
Citadel Advisors
9
Citadel Advisors
Florida
$29.2K +$37.1K +590 New
TRCT
10
Tower Research Capital (TRC)
New York
$8.27K +$3.77K +60 +56%
UBS Group
11
UBS Group
Switzerland
$6.51K +$7.99K +127 +2,540%
Morgan Stanley
12
Morgan Stanley
New York
$3.11K +$1.64K +26 +70%
BSB
13
Bangor Savings Bank
Maine
$704 – – –
Wells Fargo
14
Wells Fargo
California
$183 – – –
JP Morgan Chase
15
JP Morgan Chase
New York
$16 – – –
Group One Trading
16
Group One Trading
Illinois
$12 – – –
Bank of America
17
Bank of America
North Carolina
$5 – – –
Qube Research & Technologies (QRT)
18
Qube Research & Technologies (QRT)
United Kingdom
$2 – – –
Royal Bank of Canada
19
Royal Bank of Canada
Ontario, Canada
– +$63 +1 New

INDP Hedge Fund Activity: Q4 2023 in Review

15 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q4 2023, worth a combined $1.06M — down 32% from $1.57M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new INDP positions and 0 closed out — a net gain of 2 holders — while 5 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $37.1K. The largest seller was Investment House LLC, cutting an estimated $943.

  • 15 institutional investors held Indaptus Therapeutics (INDP) as of Q4 2023, up from 13 in Q3 2023.
  • Funds reported $1.06M of Indaptus Therapeutics stock for Q4 2023, down 32% quarter-over-quarter.
  • 2 funds opened new Indaptus Therapeutics positions in Q4 2023 and 0 closed out, a net change of +2 holders.
  • The largest Indaptus Therapeutics buyer in Q4 2023 was Citadel Advisors, an estimated $37.1K added.
  • The largest Indaptus Therapeutics seller in Q4 2023 was Investment House LLC, an estimated $943 sold.

Based on aggregated 13F filings for Q4 2023.